Patient Information - EYLEA ( Aflibercept)

Eylea is a new anti growth factor agent injected into the vitreous cavity in the same way as Lucentis. Recent trials have shown Eylea to be as effective as Lucentis in the treatment of age related macular degeneration but with the advantage of only requiring review and re treatment every 2 months.

Disclaimer
The
information provided in this website is intended as a useful aid to general
practitioners, optometrists and patients. It is impossible to diagnose and
treat patients adequately without a thorough eye examination by a qualified
ophthalmologist, optometrist or your general practitioner. Hopefully the
information will be of use prior to and following a consultation which
it supplements and does not replace.